Stem Cell Treatment for Dry AMD Fast-tracked by FDA

It was reported here in March 2017 that BioTime, Inc. is conducting a Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. OpRegen is a retinal pigment epithelium (RPE) stem cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). RPE cells are essential [Read More]

Biocurrent Therapy: A Promising Treatment for Dry AMD

by Dan Roberts with additional material by Wendy Strouse Watt, O.D. Originally Published October 26, 2005 Acuity Medical has successfully completed a proof of concept, double-masked trial of its TheraMac™ device for the treatment of dry age-related macular degeneration (AMD). The therapy developed from early studies of microcurrent stimulation, with improvements in the science and [Read More]